Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?
Level 4 - case-series / case-control
Cross-sectional observational biomarker study in a single clinical cohort without a control group.
PubMed 21855185 · doi:10.1016/j.clnu.2011.07.010
What was done
Plasma levels of four pro-inflammatory cytokines (IL-6, IL-1β, IL-8, and TNF-α), along with white blood cells, lymphocytes, C-reactive protein, and albumin, were measured in 83 advanced cancer patients (47 males, 36 females, aged 34–85 years). Participants completed questionnaires assessing weakness, appetite loss, fatigue, quality of life, and weight loss, and underwent functional testing for strength, body composition, and sarcopenia. Medical charts were reviewed to record hospital admission days and survival to assess the diagnostic and prognostic value of these markers in cancer cachexia.
What was found
The abstract reports no numerical data, effect sizes, or statistical values. It qualitatively reports that IL-1β had stronger associations than IL-6 with key clinical features of cancer cachexia, specifically weakness, loss of appetite, weight loss, and sarcopenia.
Why it matters
While IL-6 is frequently highlighted in proposed diagnostic and staging criteria for cancer cachexia, these findings suggest that IL-1β may be more clinically relevant to specific patient-reported and physical cachexia manifestations.
Limits
The sample size was modest (n = 83) across a broad age range (34–85 years), and specific cancer types were not reported in the abstract. The abstract provides no exact quantitative values, correlation coefficients, or p-values, precluding independent evaluation of the strength or precision of the reported associations.
Cited by
- supports Cancer cachexia is characterized by marked elevation of inflammatory mediators including interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha).